Abbott will take on Edwards Lifesciences and Medtronic in the US transcatheter aortic valve replacement (TAVR) market with the Portico self-expanding valve with the FlexNav delivery system.
The US Food and Drug Administration
Abbott Becomes Third US TAVR Competitor With Portico Approval
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.
